Kevin Patrick Moran Vanda Pharmaceuticals Inc. (VNDA) insider trading activity

VNDA Quotes by TradingView

Kevin Patrick Moran is SVP, CFO & Treasurer of Vanda Pharmaceuticals Inc.. Currently has a direct ownership of 328,822 shares of VNDA, which is worth approximately $1.58 Million. The most recent transaction as insider was on Mar 01, 2025, when has been sold 26,941 shares (Common Stock) at a price of $4.76 per share, resulting in proceeds of $128,239. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 329K
43.74% 3M change
42.34% 12M change
Total Value Held $1.58 Million

Kevin Patrick Moran Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 01 2025
SELL
Payment of exercise price or tax liability
$128,239 $4.76 p/Share
26,941 Reduced 7.57%
328,822 Common Stock
Feb 21 2025
BUY
Open market or private purchase
$8,780 $4.39 p/Share
2,000 Added 0.56%
355,763 Common Stock
Feb 18 2025
BUY
Grant, award, or other acquisition
-
125,000 Added 26.11%
353,763 Common Stock
Jul 29 2024
SELL
Open market or private sale
$13,325 $5.92 p/Share
2,251 Reduced 0.97%
228,763 Common Stock
Mar 05 2024
SELL
Open market or private sale
$37,388 $4.2 p/Share
8,902 Reduced 3.71%
231,014 Common Stock
Mar 04 2024
SELL
Open market or private sale
$25,975 $4.48 p/Share
5,798 Reduced 2.36%
239,916 Common Stock
Feb 16 2024
BUY
Grant, award, or other acquisition
-
125,000 Added 33.72%
245,714 Common Stock
Jul 28 2023
SELL
Open market or private sale
$13,935 $6.3 p/Share
2,212 Reduced 1.8%
120,714 Common Stock
Jun 15 2023
SELL
Open market or private sale
$100,640 $6.29 p/Share
16,000 Reduced 11.52%
122,926 Common Stock
Mar 03 2023
SELL
Open market or private sale
$37,479 $6.28 p/Share
5,968 Reduced 4.12%
138,926 Common Stock
Mar 02 2023
SELL
Open market or private sale
$49,867 $6.26 p/Share
7,966 Reduced 5.21%
144,894 Common Stock
Feb 16 2023
BUY
Grant, award, or other acquisition
-
32,700 Added 17.62%
152,860 Common Stock
Dec 06 2022
SELL
Open market or private sale
$50,843 $10.61 p/Share
4,792 Reduced 3.84%
120,160 Common Stock
Dec 06 2022
BUY
Exercise of conversion of derivative security
$23,400 $3.12 p/Share
7,500 Added 5.66%
124,952 Common Stock
Jul 28 2022
SELL
Open market or private sale
$24,562 $10.97 p/Share
2,239 Reduced 1.87%
117,452 Common Stock
Mar 02 2022
SELL
Open market or private sale
$99,625 $11.28 p/Share
8,832 Reduced 6.87%
119,691 Common Stock
Mar 01 2022
SELL
Open market or private sale
$38,863 $11.19 p/Share
3,473 Reduced 2.63%
128,523 Common Stock
Feb 28 2022
BUY
Grant, award, or other acquisition
-
32,700 Added 19.85%
131,996 Common Stock
Jul 28 2021
SELL
Open market or private sale
$40,981 $19.24 p/Share
2,130 Reduced 2.1%
99,296 Common Stock
Mar 02 2021
SELL
Open market or private sale
$110,182 $18.23 p/Share
6,044 Reduced 5.62%
101,426 Common Stock
Mar 01 2021
SELL
Open market or private sale
$61,782 $18.57 p/Share
3,327 Reduced 3.0%
107,470 Common Stock
Feb 24 2021
BUY
Grant, award, or other acquisition
-
32,700 Added 22.79%
110,797 Common Stock
KPM

Kevin Patrick Moran

SVP, CFO & Treasurer
Washington, DC

Track Institutional and Insider Activities on VNDA

Follow Vanda Pharmaceuticals Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VNDA shares.

Notify only if

Insider Trading

Get notified when an Vanda Pharmaceuticals Inc. insider buys or sells VNDA shares.

Notify only if

News

Receive news related to Vanda Pharmaceuticals Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on VNDA